EP4 receptor antagonists
Compounds of formula (I): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either -(CH2)n-X-, where n is 1 or 2 and X is O, S, S( O), S( O)2, or NRN1, where RN1 is selected from H or optionally substituted C1-4 alkyl, or Y is -C( O)NRN2-, where RN2 is selected from H, and optiona...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | SUTTON JONATHAN M FENTON GARRY OXFORD ALEXANDER W NEWTON CHRISTOPHER G HARRIS NEIL V STUTTLE KEITH A. J CLARK DAVID E COLEMAN ROBERT A CLARK KENNETH L HYND GEORGE DAVIS RICHARD J |
description | Compounds of formula (I): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either -(CH2)n-X-, where n is 1 or 2 and X is O, S, S( O), S( O)2, or NRN1, where RN1 is selected from H or optionally substituted C1-4 alkyl, or Y is -C( O)NRN2-, where RN2 is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R3 is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R5 is either: (i) carboxy; (ii) a group of formula (II): or (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted alkyl; (iv) tetrazol-5-yl. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US7858644B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US7858644B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US7858644B23</originalsourceid><addsrcrecordid>eNrjZJBwDTBRKEpNTi0oyS9SSMwrSUzPz8ssLinmYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXxocHmFqYWZiYmTkbGRCgBAKOoIf0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>EP4 receptor antagonists</title><source>esp@cenet</source><creator>SUTTON JONATHAN M ; FENTON GARRY ; OXFORD ALEXANDER W ; NEWTON CHRISTOPHER G ; HARRIS NEIL V ; STUTTLE KEITH A. J ; CLARK DAVID E ; COLEMAN ROBERT A ; CLARK KENNETH L ; HYND GEORGE ; DAVIS RICHARD J</creator><creatorcontrib>SUTTON JONATHAN M ; FENTON GARRY ; OXFORD ALEXANDER W ; NEWTON CHRISTOPHER G ; HARRIS NEIL V ; STUTTLE KEITH A. J ; CLARK DAVID E ; COLEMAN ROBERT A ; CLARK KENNETH L ; HYND GEORGE ; DAVIS RICHARD J</creatorcontrib><description>Compounds of formula (I): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either -(CH2)n-X-, where n is 1 or 2 and X is O, S, S( O), S( O)2, or NRN1, where RN1 is selected from H or optionally substituted C1-4 alkyl, or Y is -C( O)NRN2-, where RN2 is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R3 is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R5 is either: (i) carboxy; (ii) a group of formula (II): or (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted alkyl; (iv) tetrazol-5-yl.</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2010</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20101228&DB=EPODOC&CC=US&NR=7858644B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20101228&DB=EPODOC&CC=US&NR=7858644B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SUTTON JONATHAN M</creatorcontrib><creatorcontrib>FENTON GARRY</creatorcontrib><creatorcontrib>OXFORD ALEXANDER W</creatorcontrib><creatorcontrib>NEWTON CHRISTOPHER G</creatorcontrib><creatorcontrib>HARRIS NEIL V</creatorcontrib><creatorcontrib>STUTTLE KEITH A. J</creatorcontrib><creatorcontrib>CLARK DAVID E</creatorcontrib><creatorcontrib>COLEMAN ROBERT A</creatorcontrib><creatorcontrib>CLARK KENNETH L</creatorcontrib><creatorcontrib>HYND GEORGE</creatorcontrib><creatorcontrib>DAVIS RICHARD J</creatorcontrib><title>EP4 receptor antagonists</title><description>Compounds of formula (I): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either -(CH2)n-X-, where n is 1 or 2 and X is O, S, S( O), S( O)2, or NRN1, where RN1 is selected from H or optionally substituted C1-4 alkyl, or Y is -C( O)NRN2-, where RN2 is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R3 is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R5 is either: (i) carboxy; (ii) a group of formula (II): or (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted alkyl; (iv) tetrazol-5-yl.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2010</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJBwDTBRKEpNTi0oyS9SSMwrSUzPz8ssLinmYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXxocHmFqYWZiYmTkbGRCgBAKOoIf0</recordid><startdate>20101228</startdate><enddate>20101228</enddate><creator>SUTTON JONATHAN M</creator><creator>FENTON GARRY</creator><creator>OXFORD ALEXANDER W</creator><creator>NEWTON CHRISTOPHER G</creator><creator>HARRIS NEIL V</creator><creator>STUTTLE KEITH A. J</creator><creator>CLARK DAVID E</creator><creator>COLEMAN ROBERT A</creator><creator>CLARK KENNETH L</creator><creator>HYND GEORGE</creator><creator>DAVIS RICHARD J</creator><scope>EVB</scope></search><sort><creationdate>20101228</creationdate><title>EP4 receptor antagonists</title><author>SUTTON JONATHAN M ; FENTON GARRY ; OXFORD ALEXANDER W ; NEWTON CHRISTOPHER G ; HARRIS NEIL V ; STUTTLE KEITH A. J ; CLARK DAVID E ; COLEMAN ROBERT A ; CLARK KENNETH L ; HYND GEORGE ; DAVIS RICHARD J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US7858644B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2010</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>SUTTON JONATHAN M</creatorcontrib><creatorcontrib>FENTON GARRY</creatorcontrib><creatorcontrib>OXFORD ALEXANDER W</creatorcontrib><creatorcontrib>NEWTON CHRISTOPHER G</creatorcontrib><creatorcontrib>HARRIS NEIL V</creatorcontrib><creatorcontrib>STUTTLE KEITH A. J</creatorcontrib><creatorcontrib>CLARK DAVID E</creatorcontrib><creatorcontrib>COLEMAN ROBERT A</creatorcontrib><creatorcontrib>CLARK KENNETH L</creatorcontrib><creatorcontrib>HYND GEORGE</creatorcontrib><creatorcontrib>DAVIS RICHARD J</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SUTTON JONATHAN M</au><au>FENTON GARRY</au><au>OXFORD ALEXANDER W</au><au>NEWTON CHRISTOPHER G</au><au>HARRIS NEIL V</au><au>STUTTLE KEITH A. J</au><au>CLARK DAVID E</au><au>COLEMAN ROBERT A</au><au>CLARK KENNETH L</au><au>HYND GEORGE</au><au>DAVIS RICHARD J</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>EP4 receptor antagonists</title><date>2010-12-28</date><risdate>2010</risdate><abstract>Compounds of formula (I): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either -(CH2)n-X-, where n is 1 or 2 and X is O, S, S( O), S( O)2, or NRN1, where RN1 is selected from H or optionally substituted C1-4 alkyl, or Y is -C( O)NRN2-, where RN2 is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R3 is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R5 is either: (i) carboxy; (ii) a group of formula (II): or (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted alkyl; (iv) tetrazol-5-yl.</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng |
recordid | cdi_epo_espacenet_US7858644B2 |
source | esp@cenet |
subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
title | EP4 receptor antagonists |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T01%3A27%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SUTTON%20JONATHAN%20M&rft.date=2010-12-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS7858644B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |